Price T Rowe Associates Inc Ocugen, Inc. Call Options Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding OCGN
# of Institutions
118Shares Held
75.1MCall Options Held
200KPut Options Held
151K-
Black Rock Inc. New York, NY17.9MShares$17.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA16.7MShares$16 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.89MShares$6.61 Million0.0% of portfolio
-
State Street Corp Boston, MA5.93MShares$5.69 Million0.0% of portfolio
-
Ubs Group Ag4.37MShares$4.19 Million0.0% of portfolio
About Ocugen, Inc.
- Ticker OCGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 216,566,000
- Market Cap $208M
- Description
- Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...